Open Orphan (LSE:ORPH) Open Orphan has won a flu human challenge study contract worth £2.5 million with an unnamed US biotech. The study will be carried out by subsidiary hVIVO at the group’s...

Open Orphan (LSE:ORPH) Open Orphan has won a flu human challenge study contract worth £2.5 million with an unnamed US biotech. The study will be carried out by subsidiary hVIVO at the group’s...
Open Orphan (LSE:ORPH) Open Orphan bounced back by 6.6% on Friday morning after announcing an extension of its relationship with a tier 1 German pharmaceutical company. The pharmaceutical services...
Tuesday saw Open Orphan (LSE:ORPH) reveal a transformational Covid-19 vaccination contract with the UK government that could be worth up to £40 million. The first part of the contract will see Open...
Open Orphan (LSE:ORPH) shot up to record highs on Monday morning after unveiling a £4.3 million contract with a global top ten vaccine company. Shares in the pharmaceutical services player have been...
Open Orphan (LSE:ORPH) has confirmed that it is in advanced negotiations with the UK government for a coronavirus challenge study. In a Thursday update in response to a spike in its share price, the...
Huge biotech potential at XPhyto Therapeutics (CSE:XPHY | OTC:XPHYF | FSE:4XT) Biotechs are among the most profitable, highest-margin businesses on earth. Why? Exclusivity and first-mover advantage....
Anglo-Irish contract research pharma group Open Orphan (LSE:ORPH) has received another boost as key human challenge study expert Adrian Wildfire rejoins the team. Mr Wildfire left Open Orphan...
Open Orphan (LSE:ORPH) has signed new laboratory contracts for its London virology clinic, extending up a new area of business for the pharma services firm. A Tuesday morning RNS detailed how...
Investors are at the accumulation stage with Open Orphan (LSE:ORPH), as shares in the Anglo-Irish contract research organisation hold steady at around 12p. Open Orphan has not seen the same...